Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 July 2020 | Story Nonsindiso Qwabe | Photo Charl Devenish
Ronet Vrey.

She is affectionately called ‘Tannie Ronet’ by the dozens of students coming her way, and Faculty of Education librarian Ronet Vrey would not have it any other way. While Vrey loves to remain behind the scenes, her passion for students makes her a big hit with every student crossing her path at the University of the Free State Library and Information Services on the Bloemfontein Campus. 

Vrey has been a librarian for as long as she can remember; a path she says was inspired by her educator mother. But instead of standing in front of a class, she gets to invest in students' academic journeys by being a helping hand in times of need. She is a UFS alumna, having graduated in 1988 with a degree in Library and Information Sciences, specialising in Education, Library Services, and Technology. 

"I was interested in library information services because back then, we were exploring the use of computers and moving in the direction of technology. Little did we know about digitisation and curation that would follow."

In 2005, she started working as librarian for the Faculty of the Humanities, before working jointly for the Faculties of the Humanities and Education. Since 2011, she has focused solely on the Faculty of Education, serving as the link between the library and the faculty. "I am supposed to focus only on students from the first year to honours level, but because of the relationships built there, many students often choose to stay with me. When they come to me for help, I don't say no," she says.

Information literacy a lifelong skill

Vrey shares the love for her job with her fellow librarians from other faculties. In 2019, the group presented a paper on embedded librarianship at the International Conference on Information Literacy (ICIL). She said they are in the process of having their paper published. "We want to be embedded in faculties in order to make students at the UFS information literate. If we can teach students information literacy skills to help themselves, we will have lifelong learners who can develop all the time, and you would have established a community of lifelong learners," she said.

One student who has benefited from Vrey's dedication and passion for students, is Dr Norma Lehasa, who obtained her PhD in 2019 after a seven-year journey due to ill health.

Vrey known as beacon of hope

Lehasa met Vrey in 2016, and says she owes her success to the likes of Vrey. Lehasa said each year when students graduate, it is people like Vrey who are supporting them behind the scenes to reach their goals. 

"My wonderful librarian, Ronet, made me focus and never give up. She used to go the extra mile for me, even teaching me how to use the resources to search for literature myself. The outcome of me being a Doctor of Philosophy today is because of people like Ronet. People like her need to be recognised for the good work that they do," Lehasa said.
Lehasa's PhD topic was: An Adult Learning Perspective on Professional Development in the Human Resources Department of the Free State Premier.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept